| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from exchange and issuance of warrants, net | - | 0 |
| Deferred offering costs | 49,308 | 0 |
| Net cash provided by financing activities | 1,931,548 | 1,980,856 |
| Net increase in cash and cash equivalents | 54,554 | 1,007,361 |
| Cash and cash equivalents at beginning of period | 547,890 | - |
| Cash and cash equivalents at end of period | 602,444 | - |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)